ArticleeLife2021
Improving preclinical studies through replications.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents.eLife · 2025Pooled it
- Pooled it
- Evaluation of the replicability of systematic reviews with meta-analyses of the effects of health interventions.Research synthesis methods · 2026Article
- Peer replication : A new tier of science built on reproducibility.EMBO reports · 2026Article
- Celiac Disease as a Model of Intestinal Malnutrition: Mechanisms and Nutritional Management.Nutrients · 2025Review
- Laboratory and physiological aspects of substitute metazoan models for in vivo pharmacotoxicological analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Assessing the effects of fluids and antibiotics in an acute murine model of sepsis: study protocol for the National Preclinical Sepsis Platform-01 (NPSP-01) Study.F1000Research · 2025Article
- Strengthening translational preclinical research through confirmatory multi-laboratory studies.Frontiers in medicine · 2025Article
- Article
- Reproducible lung protective effects of a TGFβR1/ALK5 inhibitor in a bleomycin-induced and spirometry-confirmed model of IPF in male mice.Physiological reports · 2024Article
- Building reproducible bridges to cross the "valley of death".The Journal of clinical investigation · 2024Article
- Growth capacity of a Wharton's Jelly derived mesenchymal stromal cells tissue engineered vascular graft used for main pulmonary artery reconstruction in piglets.Frontiers in bioengineering and biotechnology · 2024Article
- Reducing the false discovery rate of preclinical animal research with Bayesian statistical decision criteria.Statistical methods in medical research · 2023Article
- Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment.Journal of clinical medicine · 2023Review
- A preclinical randomized controlled multi-centre trial of anti-interleukin-17A treatment for acute ischaemic stroke.Brain communications · 2023Article
- Preclinical trials in Alzheimer's disease: Sample size and effect size for behavioural and neuropathological outcomes in 5xFAD mice.PloS one · 2023Article
- Cell-3D matrix interactions: recent advances and opportunities.Trends in cell biology · 2022Review
- Hamster models of COVID-19 pneumonia reviewed: How human can they be?Veterinary pathology · 2022Review
- A multiparametric calcium signal screening platform using iPSC-derived cortical neural spheroids.SLAS discovery : advancing life sciences R & D · 2022Article
- Do German university medical centres promote robust and transparent research? A cross-sectional study of institutional policies.Health research policy and systems · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of preclinical research is to inform the development of novel diagnostics or therapeutics, and the results of experiments on animal models of disease often inform the decision to conduct studies in humans. However, a substantial number of clinical trials fail, even when preclinical studies have apparently demonstrated the efficacy of a given intervention. A number of large-scale replication studies are currently trying to identify the factors that influence the robustness of preclinical research. Here, we discuss replications in the context of preclinical research trajectories, and argue that increasing validity should be a priority when selecting experiments to replicate and when performing the replication. We conclude that systematically improving three domains of validity - internal, external and translational - will result in a more efficient allocation of resources, will be more ethical, and will ultimately increase the chances of successful translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.